Showing 5321-5330 of 8787 results for "".
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate i
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- FDA Approves Paratek's Nuzyrahttps://practicaldermatology.com/news/fda-approves-parateks-nuzyra/2457579/The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and or
- Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis/2457582/Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adul
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- Bellus Medical Now Part of Crown Laboratorieshttps://practicaldermatology.com/news/bellus-medical-now-part-of-crown-laboratories/2457590/Crown Laboratories, Inc. and Hildred Capital Partners, LLC have acquired Bellus Medical. Bellus’s non-invasive offerings include the SkinPen, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the f
- Candela and Vascular Birthmark Foundation Offer Pro Bono Laser Treatments for Patients in Needhttps://practicaldermatology.com/news/candela-and-vascular-birthmark-foundation-offer-pro-bono-laser-treatments-for-patients-in-need/2457593/Candela Corporation is partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th A
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for appr
- Neova Launches New Line of Professional Grade Peelshttps://practicaldermatology.com/news/neova-launches-new-line-of-professional-grade-peels/2457604/Neova SmartSkinCare has introduced a new range of Professional Treatments developed exclusively for dermatologist use. The line of five new exfoliating peels integrate the newest and most advanced formulas with proven, established ingredients to produce visible results with minimal irritation and